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Purpose: the main purpose of this study was to diagnose pre-sarcopenia in cancer patients who had lack of computed tomography (CT) abdominal 
images, with a newly discovered method based on cervical images.
Material and methods: a sample of 37 patients with either lung cancer or a cancer that affected the upper digestive system underwent 
radiotherapy computed simulation which included measurements at C3 and L3 regions. Skeletal muscle mass (SMM) and skeletal muscle index 
(SMI) were determined by Hounsfield units and compared in both regions. Pre-sarcopenia was identified according to the cut-points currently 
established: ≤ 41 cm2/m2 in females, ≤ 43 cm2/m2 in males with a BMI ≤ 25 kg/m2, and ≤ 53 cm2/m2 in males with a BMI > 25 kg/m2.
Results: the correlation of SMM and SMI between the C3 and L3 regions was R2 = 0.876 and R2 = 0.805, respectively. Moreover, there was 
a positive association (86.49%) in terms of the diagnosis of pre-sarcopenia according to both regions. In total, eleven pre-sarcopenic patients 
(29.37%) were identified; three of them being overweight (27.27%) and two of them being obese (18.18%).
Conclusion: a single sectional cross at the level of C3 can be used for the diagnosis of pre-sarcopenia. This new method avoids unnecessary irradia-







Propósito: el propósito de este estudio fue diagnosticar la presarcopenia en pacientes con cáncer que no disponen de imágenes por tomografía 
computarizada (TC) a nivel abdominal mediante un método novedoso basado en cortes a nivel cervical.
Material y métodos: se analizaron y se compararon mediante unidades la masa muscular y la masa muscular esquelética en 37 pacientes 
con cáncer de pulmón y neoplasias del aparato digestivo superior que incluían cortes en la TC de planificación a nivel de C3 y L3. La pre-
sarcopenia se identificó de acuerdo con los puntos de corte establecidos actualmente: ≤ 41 cm2/m2 para mujeres, ≤ 43 cm2/m2 en hombres 
con un IMC ≤ 25 kg/m2 y ≤ 53 cm2/m2 en hombres con IMC > 25 kg/m2.
Resultados: la correlación de la masa muscular y el índice musculoesquelético entre las regiones C3 y L3 fue R2 = 0.876 y R2 = 0.805, 
respectivamente. Además, hubo una asociación positiva (86,49%) en términos del diagnóstico de presarcopenia según ambas regiones. En total, 
se identificaron once pacientes con presarcopenia (29,37%); tres de ellos con sobrepeso (27,27%) y dos con obesidad (18,18%).
Conclusión: un solo corte transversal a nivel de la vértebra C3 puede diagnosticar la presarcopenia. Este nuevo método evita la irradiación 
innecesaria, ahorra costos hospitalarios y detecta la desnutrición antes de iniciar el tratamiento de radioterapia en pacientes con cáncer que no 
disponen de imágenes a nivel abdominal.
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INTRODUCTION
Cancer cachexia (CC) is a multi-factorial syndrome generally 
defined by an ongoing loss of muscle mass, with or without loss of 
fat mass, often accompanied by anorexia, weakness and fatigue, 
which leads to progressive functional impairment (1). On the other 
hand, sarcopenia is a syndrome characterized by progressive and 
generalized loss of skeletal muscle mass (SMM) and strength, 
with a risk of adverse outcomes such as physical disability, poor 
quality of life and death (2).
Skeletal muscle is the body compartment where most of the 
contraction of lean body mass occurs and is characterized by 
increased protein breakdown and by depression in protein syn-
thesis (3). There are several reasons for muscle mass depletion 
in cancer patients, such as higher energy expenditure, anorexia, 
inflammation and unbalanced cancer metabolism (4,5). 
Sarcopenic patients are at a higher risk of increased toxicity 
from anti-neoplastic treatments (5-7), requiring smaller doses or 
delays that may reduce treatment efficacy (5). Due to this diverse 
and new scenario in oncology, new methods and techniques such 
as computerized tomography (CT) scans have been explored to 
assess lean body mass and body composition (8). In 2004, Shen 
et al. demonstrated that single-slice tissue areas at the level of 
the third lumbar vertebral (L3) were strongly correlated with the 
total body SMM (8,9). Consequently, Prado et al. established 
for the first time cut-points for SMM related to mortality risk 
using CT derived data. These cut-offs were updated and used 
to assess low muscle mass according to skeletal muscle index 
(SMI), being ≤ 41 cm2/m2 in females and ≤ 43 cm2/m2 for males 
with a BMI ≤ 25 kg/m2, and ≤ 53 cm2/m2 for males with a BMI 
> 25 kg/m2 (6). 
On the other hand, low SMM may also be present even in the 
presence of normal weight/overweight. Sometimes, individuals 
may show an appropriate or elevated BMI, but they whether 
present low muscle mass or muscle mass loss. This condition, 
called sarcopenic obesity, has been reported to have higher 
rates of complications and hospital costs than normal weight 
patients, an observation in accordance with the obesity para-
dox (10). Additionally, cancer is associated with alterations in 
hormones that may cause muscle loss and alter fat metabolism 
(11). These findings underscore the value of CT-defined quan-
tification of muscle, as opposed to overall body weight or body 
mass index (BMI). 
Currently, CT-scans at L3 level are reliable for the assessment 
of SMM, but unfortunately they are seldom available for all cancer 
patients, as occurs in head and neck cancer (HNC) patients, who 
are at high risk of malnutrition especially when undergoing radio-
chemotherapy (10). Very recent studies have established a good 
relationship between C3 and L3, using a formula that estimates 
SMM at the level of C3 (12).
As all cancer radiation treatment plans depend on patient char-
acteristics and need to be individualized, the main purpose of this 
study was to correlate the muscle mass between a single axial 
cross at C3 and L3 level. Secondarily, our aim was to identify 
the prevalence of pre-sarcopenia in cancer patients, using CT 
planning scans as a tool. 
MATERIAL AND METHODS
PATIENT POPULATION
This is a retrospective cohort pilot study with 37 patients re-
ferred for radiotherapy treatment with lung cancer and cancers 
that affect the upper digestive system (pancreas, esophagus, 
stomach), between 2015 and 2017. All patients underwent vir-
tual CT simulation with CT planning scan measurements at the 
level of C3 and L3 area. 
The following clinical characteristics at the time of the CT scan 
were recorded: age (> 18 years old), tumor stage, height, weight 
loss preceding diagnosis, number of chemotherapy cycles, dose 
of radiation and surgical outcome. Reported weight and height 
were used to calculate BMI in kg/m2 and the categories applied 
to older adults were: < 18.45 as underweight; 18.5 kg/m2 to 
24.9 kg/m2 as normal weight; 25.0 kg/m2 to 29.9 kg/m2 as 
overweight; and ≥ 30.0 kg/m2 as obese.
All included patients underwent CT planning scan and were 
evaluated for the first time at a radiotherapy department for the 
radiotherapy treatment delineation. No one of them had received 
any cycle of chemotherapy.
The inclusion criteria were: age over 18 years old, diagnosis 
of digestive or lung cancer submitted to radiotherapy treatment 
planning scan and patients with anthropometry measurements 
at the moment of the CT simulation.
 Patients without all clinical data such as weight (kg) or height 
(m), or without suitable CT examinations at any levels (C3 or L3) 
(for example: unclear CT scan image, without all muscles delim-
ited, granny contrast and images with cut-off skeletal muscle) 
were excluded from the present study. 
This ensured that, in total, 19 patients were excluded be-
cause they were wheelchair-bound or bedridden, as well as 
uncooperative, with diseases such as senile dementia, stroke, 
or body paralysis.
According to the treatment planning, most therapy methods 
of our cancer patients were surgery followed by concomitant ra-
dio-chemotherapy. A sample of 28.57% of patients had received 
surgery before coming to our radiotherapy department for the adju-
vant treatment planning. On the other hand, a sample of 46 (94%) 
patients had not received any surgery yet, and they were con-
sidered for neoadjuvant radiochemotherapy or radical treatment. 
According to the radio-chemotherapy schedule, most patients were 
assessed to receive 5-fluoaracil (5-FU) and gemcitabine as first line 
chemotherapy, and mean radiation therapy dose was 50.4 Grays 
(Gy) in 28 fractions. In addition, 6.12% of lung cancer patients were 
programmed to receive stereotactic body radiotherapy (SBRT) with 
30 Gy as mean radiotherapy, divided in five fractions. Although 
most of our patients (95, 92%) received curative therapies, there 
was also a little sample (four, 04%) that received treatment for 
palliative care and symptom control.
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CT PLANNING SCAN MEASUREMENTS
Determination of C3 and  
L3 SMM using CT planning scan
CT planning refers to the process where all patients undergo 
simulation in a computer tomography simulator, which is capable 
of scanning the treatment position and interfacing with a radio-
therapy treatment planning system. All images were used for the 
measurements and plans for the radiotherapy treatment (without 
an extra irradiation for our study). 
CT is an imaging procedure that uses X-rays to create detailed 
scans of cross-sectional regions inside the body. Within the scan, 
skeletal muscle, adipose depots, bone, and organs are differenti-
ated based on each tissue’s specific attenuation values, recorded 
as Hounsfield units (HU) (13,14). Skeletal muscle was identified 
using standard HU ranges, being -29 to +150 HU (14,15). Ret-
Figure 1.
Example of C3 and L3 delineation using volume tool. In image A, the paravertebral muscles (blue) and the SCM muscles (red) are delineated. In image B, the spinal vertebrae, 
transverse abdominus, external/internal oblique and rectus abdominus muscles were delineated (purple). The settings used for delineation were of -29 to +150 HU. The sum 
of the volumes of every muscle of the region divided by the CT cut intervals expressed in mm was calculated to find out the density of SMM in C3 and L3. We propose that 
automatic methodology identification and delineation should be used when investigating SMM using CT scans, instead of free hand delineation.
A
B
rospectively, delineation of the muscles was performed manually 
by an expert at C3 and L3 vertebras, using MIM® 6.7 radio-
therapy contouring software as working tool (MIM Software Inc., 
Cleveland, OH). This is an available tool in many radiotherapy 
department, and other authors also use it for body composition 
measurements (16). CT images were acquired at cut different 
intervals expressed in mm. After delineation, to get the SMM in 
a CT scan, the cross-selectional area (CSA) of the muscles was 
retrieved as the total sum of delineated pixels divided by CT slice 
thickness (17). An example of how tissues were measured with 
MIM® software is shown in figure 1. 
The CSA at C3 region includes the paravertebral muscles (PVM) 
and the sternocleidomastoid (SCM) muscles, measured separate-
ly. The CSA at L3 includes psoas and spinal vertebrae, as well as 
transversus abdominus, external and internal oblique, and rectus 
abdominus muscles. In sum, the single cross-sectional L3 verte-
bra is highly associated with total body skeletal muscle. 
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Estimation of SMM at L3 level determined 
according to C3 measurements
SMM at L3 level was determined for each patient according 
to the formula previously described by Swartz et al., after es-
tablishing a multivariate linear regression model between the 
CSA at C3 level and the CSA at the L3 level (12). This formula 
showed a positive correlation between both levels (r = 0.891, 
p < 0.001), if patient age, weight, and sex is known (10,12). 
SMM at L3 according to C3 (cm2) = 27.304 + 1.363*SMM 
at C3 (cm2) - 0.671*age (y) + 0.640* weight (kg)  
+ 26.442*sex (man = 2, woman = 1)
Determination of SMI at L3 level
The SMI (cm2/m2), also called skeletal muscle lumbar index, 
was calculated by summing the cross-sectional area of the skel-
etal muscles on an axial CT image at the L3 level, standardized 
by height (18). The used formula for this equation is detailed 
below:
SMI (cm2/m2): SMM at L3 level (cm2)/height (m)2
Men with SMI less than 43 cm2/m2 (BMI ≤ 25 kg/m2) and 53 
cm2/m2 (BMI > 25 kg/m2), respectively, and women with SMI 
less than 41 cm2 /m2 were considered as sarcopenic patients (6).
STATISTICAL ANALYSIS
The different variables in the study were analyzed with de-
scriptive statistics and the continuous variables were represent-
ed by mean, median, standard deviation and percentiles. The 
descriptive results were stratified by sex as it is shown. The ad-
justments of the variables to normality were done with the Sha-
piro-Wilk test. A Pearson correlation was calculated between 
the muscle mass findings in C3 and L3, to study the association 
between the two. The statistical program Stata 14 was used for 
the analysis.
ETHICAL CONSIDERATIONS
All data, including the CT-scans, were used in an anonymized 
mode. Moreover, our study is concerned with retrospective data 
of patients suffering from cancer, which is an illness with high 
morbidity and mortality. Because this is a retrospective study 
and CT images were used for the measurements and plans for 
the radiotherapy treatment (without an extra irradiation), the 
informed consent was not necessary according to the laws and 
Best Practice guidelines. However, the study was approved by 
the Ethics Committee. 

































































































*TNM: classification of malignant tumors. Primary tumor (t), regional 
lymphonode (n) and distant metastasis (m). †Chronic obstructive pulmonary 
disease (COPD). ‡Benign prostatic hyperplasia (BPH). §Chronic coronary 
artery disease (CAD). ǁHuman immunodeficiency virus (HIV).
RESULTS
A total of 37 patients (six women and 31 men) were enrolled in 
this retrospective study. Table I shows the demographic and clin-
ical characteristics of the sample, including cancer stage and 
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classification of malignant tumors (TNM) determined according to 
the American Joint Committee on Cancer staging manual (7th edi-
tion). Third cancer stage (EIII) was the most common stage of 
cancer patients with 62.16%, and 8.11% presented distant me-
tastasis. Most of individuals had lung cancer (62.16%) and 14 
(37.84%) had cancers that affected the digestive system. About 
secondary disease, different pathologies were present, being hy-
pertension (14 patients), diabetes mellitus (seven patients) and 
dyslipidemia (six patients), the most common. 
All body composition measurements are presented in table II. 
The results were comparable in sex distribution, weight (kg) and 
BMI (kg/m2). Mean age of the patients was 67 years old (range 
44-86 years), mean weight was 69.84 (± 12.21) kg, and mean 
BMI was 25.28 (± 4.38) kg/m2. 
Assessment of skeletal muscles at C3 level was successful in all 
patients and at L3 level was successful in 94.59% of them. Mean 
CSA at the third cervical vertebra was 44.99 (± 6.42) cm2 and at 
the third lumbar vertebra was 135.49 (± 26.42) cm2. After applying 
the developed formula (SMM at L3 according to C3), mean SMM 
at the third lumbar vertebra became 137.57 (± 24.48) cm2. Re-
garding the diagnosis of pre-sarcopenia, mean SMI measured at 
L3 was 49.07 (± 7.69) cm2/m2 and mean SMI of L3 estimated 
formula was 49.77 (± 6.47) cm2/m2.
On the other hand, the correlation between SMM at C3 and L3 
was R² = 0.876 (Fig. 2). Moreover, the SMI of both showed a 
positive correlation, with R² = 0.805 (Fig. 3). Therefore, when 
identifying patients with pre-sarcopenia by using SMI measured 
at L3 level and those obtained through the estimation, there was 
a 86.49% diagnostic correlation (32 of 37 patients were equally 
assigned). 
In addition, considering only the SMI mediations at the level of 
L3, 11 patients with low muscle mass or pre-sarcopenia (29.37%) 




















Mean 66.11 68.84 25.28 44.99 137.57 49.77 135.49 49.07
SD 11.66 12.21 4.39 8.45 24.48 6.42 26.43 7.69
Median 65.00 72.00 24.76 43.80 136.65 49.64 135.50 47.93
IQ25 Range 59.00 60.90 22.66 39.03 124.42 45.17 109.50 42.82
IQ75 Range 75.00 76.50 28.40 50.00 158.63 53.57 156.60 52.69
*BMI (kg/m2): body mass index. †CSA C3 (cm2): cross sectional area at C3 = sum of paravertebral and sternocleidomastoid muscles divided by CT slice thickness. ‡SMM 
C3 formula (cm2) = skeletal muscle mass at C3 according to the developed = [27.304 + 1.363 * CSA at C3 (cm2) – 0.671 * Age (y) + 0.640 * weight (kg) + 26.442 * 
Sex] (Sex = value ‘‘1” for female sex and ‘‘2” for male sex). §Vertebral SMI (cm2/m2) = vertebral skeletal muscle index = {[27.304 + 1.363 * CSA at C3 (cm2) – 0.671 
* Age (y) + 0.640 * weight (kg) + 26.442 * Sex] /(stature)} 2. ǁSMM L3 (cm2) = skeletal muscle mass at L3 = sum of spinal vertebrae, transverse abdominus, external/
internal oblique, and rectus abdominus muscles divided by CT slice thickness. ¶Lumbar SMI (cm2/m2) = lumbar skeletal muscle index = [SMM at L3/(stature)] 2.
Figure 2.
Analysis of skeletal muscle mass at C3 and L3 level. Estimation of SMM at L3 
using a developed formula. There was a significant correlation (r2 = 0.8769) 
between the cross-sectional area of the muscles at C3 and L3 level.
Figure 3.
Analysis of skeletal muscle index at C3 and L3 level. Estimation of SMI at L3 using 
a developed formula. There was a significant correlation (r = 0.8052).
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were identified, 54.54% of them being normal weight (with a 
BMI < 25 kg/m2) and 45.45% being overweight (with a BMI 
> 25 kg/ m2). According to sex distribution, most of pre-sarco-
penic individuals were men (ten men and one woman).
DISCUSSION
Skeletal muscle is one of the largest organs of the body and 
is involved in metabolic processes in health and disease (19). 
Sarcopenia is the major feature of cancer cachexia and is related 
with reduced quality of life and survival (8,10,20). The evidence 
strongly suggests that SMM is associated with clinical outcomes 
in cancer patients. Reduction in lean body mass causes a lower 
body functional capacity, higher toxicity from antineoplastic treat-
ments and lower survival, and, therefore, has been consistently 
associated with a poor disease prognosis (2,21). 
The L3 lumbar vertebra landmark is often used in cross-sec-
tional body composition analysis and is found to correspond to the 
whole-body muscle tissue measurement (6,22). CT-scans at L3 
level are seldom available in all cancer patients as, for example, 
occurs in head and neck patients (11), who are at elevated risk 
of malnutrition (23,24). 
Previous studies have already investigated the correlation 
between the SMM at C3 and L3 vertebras and a multivariate 
linear regression between both levels, with a positive correlation 
(10,12). Therefore, we also investigated whether C3 muscle CSA 
correlates with L3 muscle CSA on an extended CT planning scan, 
and we also found a good correlation. To date, this is the first pilot 
study which compares the SMM and the SMI in two different 
regions using the same CT body scan. Moreover, according to 
the diagnosis of pre-sarcopenia, there was a strong correlation 
between the SMI of both locations, and 86.49% of cancer patients 
were equally assigned. Perhaps, the presence of comorbidities, 
as for example ascites or edema, which appears so frequently in 
cancer patients and courses with weight gain, could be the reason 
of the unequal classification of the only five patients who do not 
present a good correlation. 
Moreover, patients with cancer present malnutrition associated 
not only with the characteristics that define the malignant tumor, 
but also with the treatment which must be applied. Side effects 
of radiation depend on the tumor location, total dose and the ef-
fects of combined radiochemotherapy. Depending on the location, 
patients have big limitations on eating (as for example head and 
neck and esophagus cancer patients). Consequently, monitoring 
body composition before radiotherapy could be very useful for 
nutritional and medical interventions, to optimize treatment and 
reduce toxicity levels (25). 
On the other hand, low levels of muscle mass are not only seen 
in patients who appear thin or cachectic, but also in individuals 
who are overweight (BMI > 25 kg/m2) or obese (BMI ≥ 30 kg/m2) 
(5,7,8). Sarcopenic obesity is strongly related to reduced survival 
(26,27), worse prognosis (15,2), and important adverse effects 
(27,28). The sarcopenic obese phenotype has been increasingly 
identified among cancer patients (15,20), probably because of the 
growing prevalence of obesity worldwide combined with intense 
muscle catabolism promoted by cancer treatment and/or the dis-
ease itself (9,29,30). In this context, numerous techniques have 
been developed to provide objective measures. Moreover, other 
anthropometric quantification methods used to diagnose muscle 
depletion, such as bioelectrical impedance analysis (BIA) or waist 
circumference (WC), have a significant inter and intra observer 
variability, and this may limit sensitivity for detecting changes and 
sarcopenic obesity (2,18,31). According to new investigations, 
magnetic resonance (MR) and CT are the most reliable methods 
for the diagnosis of sarcopenia because they can reveal quantita-
Figure 4.
A.Patient without pre-sarcopenia. B. Patient with pre-sarcopenia. Examples of 
cross-sectional third vertebra (C3) images. Musculature delineated with MIM® radi-
otherapy contouring software. Patients exhibited wide variation in SMM composition. 
A
B
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tive and qualitative changes in muscle mass (32). As CT planning 
scans are routinely used at radiotherapy department, they can be 
used to assess skeletal muscle volume as well as a specific and 
particular method in patients undergoing radiotherapy. This new 
system permits clinicians to immediately calculate this with a single 
image acquisition, without extra radiation (Fig. 4). These images 
offer great precision and their analyses are unaffected by inter-
personal variations when automatic determinations are performed.
In conclusion, in our study a low SMM was present in eleven 
patients (29.73%), 45.45% being not underweight: three of them 
with a BMI over 25 kg/m2 (27.27%) and two of them with a BMI 
≥ 30 kg/m2 (18.18%). This is the reason why this technique may 
be useful to identify patients at nutritional risk, which may not be 
suspected by visual inspection. As body composition is an import-
ant component and independent predictor of clinical outcomes in 
cancer patients, future research and clinical directions must be 
oriented in changing the use of body weight or BMI by CT scan im-
ages. Furthermore, further studies at C3 are needed, especially in 
head and neck patients, to observe the variability of muscle mass 
at this level. The presence of edema, tumor location or surgical 
operation before radiation therapy at the level of paravertebral and 
sternocleidomastoid muscles (as, for example, in laryngeal cancer) 
could increase or decrease SMM measurements. 
Our study has several limitations: on one hand, delineation of 
the muscles was performed manually by only one researcher. On 
the other hand, the recent consensus of sarcopenia emphasizes 
the importance of evaluating muscle performance and strength 
as sarcopenia is characterized by low muscle mass plus low 
muscle strength or low physical performance (2). As our current 
study evaluated the muscle mass, and not the muscle quality or 
strength, we used the term “pre-sarcopenia” according to the 
European consensus guideline. 
Likewise, despite the limited sample size of our study, the findings 
could be very important for many further investigations especially in 
patients who have lack of abdominal images (commonly used now-
adays as the gold standard, but not feasible for all the patients who 
could present malnutrition). Body composition analysis at new CT 
levels would be an important step for the future translation to clinical 
practice in cancer patients undergoing radiotherapy treatment.
As we have shown in this paper, there was a good correlation 
between SMM in C3 and L3, which means that a single sectional 
cross at the level of the third vertebra can be used to diagnose 
pre-sarcopenia in patients who have lack of an axial cut at the level 
of the third lumbar vertebra. Due to these findings, our current study 
used a new method to reliably estimate muscle mass and lumbar 
SMI, without the need of additional imaging and patient burden.
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